For panic disorder, SSRIs are first-line because they reduce panic frequency and intensity durably over weeks and don't produce dependence. Benzodiazepines work in minutes but produce tolerance, dependence, and severe withdrawal; sustained monotherapy with a benzodiazepine for panic disorder rarely succeeds. The most common clinical pattern is an SSRI plus CBT, sometimes with a short-term benzodiazepine as a bridge during the four to six weeks before the SSRI takes effect.
The short version
The choice isn't really benzodiazepine versus SSRI in the sense of two equivalent options. It's symptomatic relief versus durable treatment, with a real role for symptomatic relief in narrow, time-limited use. The panic disorder overview lays out the broader treatment picture; this page focuses on the medication trade-off specifically.
How they differ
Mechanism and timeline
SSRIs block the serotonin transporter and over weeks reduce reactivity in the brain's threat-detection circuitry. The therapeutic effect develops over four to six weeks at a stable dose. The mechanism is described in how CBT and SSRIs work.
Benzodiazepines enhance GABA at GABA-A receptors and produce calming within 20 to 30 minutes. The effect of a single dose lasts hours; the underlying condition is unchanged. The class-level picture is in Benzodiazepines for anxiety. To compare the two side by side, PsychiatryRx has an interactive guide to how benzodiazepines and SSRIs work.
Effect on panic frequency
SSRIs at adequate dose for adequate duration typically reduce panic frequency by 50% or more and reduce attack intensity. Many patients become attack-free over months. sertraline, paroxetine, and fluoxetine have the largest evidence base in panic disorder; see Zoloft for anxiety for sertraline specifically.
Benzodiazepines reduce the intensity of a panic attack if taken at onset and reduce baseline anxiety while drug levels are adequate. They don't retrain the brain's threat-detection circuitry. When the dose effect wanes, the underlying pattern returns.
Dependence
SSRIs don't produce addiction. They produce physical adaptation, which is why they require a gradual taper to stop.
Benzodiazepines produce both physical dependence (within weeks of regular use) and significant risk of psychological dependence and misuse. Abrupt discontinuation after sustained use can produce severe withdrawal including seizures.
Safety profile
SSRIs have a wide safety margin in overdose. The FDA boxed warning on increased suicidal ideation in patients under 25 in the first months applies but doesn't change the overall favorable risk-benefit profile. The NIMH overview of mental health medications addresses both classes.
Benzodiazepines have a narrower safety margin. The FDA boxed warning specifically addresses the risk of fatal respiratory depression when combined with opioids or alcohol, and the dependence and withdrawal risks. Older adults are particularly vulnerable.
When an SSRI is the right choice
- Most patients with panic disorder, as first-line monotherapy or combined with CBT
- Patients seeking durable, non-dependence-producing treatment
- Patients with co-occurring depression
- Patients with a history of substance use disorders, where benzodiazepines are best avoided
When a benzodiazepine has a role
- Short-term bridging during the four to six weeks before an SSRI takes effect, typically with a longer-acting agent such as clonazepam
- Specific severe acute episodes where rapid relief matters more than the dependence trajectory
- A narrow subset of patients with severe refractory panic disorder where multiple SSRIs and CBT haven't produced adequate response
In none of these scenarios is sustained benzodiazepine monotherapy the goal.
What about CBT
For panic disorder specifically, cognitive behavioral therapy with interoceptive exposure is one of the most effective treatments available. Effect sizes are comparable to SSRIs, and the durability of effect after treatment ends often exceeds medication. The American Psychological Association overview of psychotherapies describes the evidence base.
The standard of care for moderate-to-severe panic disorder is an SSRI plus CBT, with optional short-term benzodiazepine bridging. CBT alone is reasonable for milder presentations.
What if SSRIs don't work
If two SSRIs at adequate doses haven't produced response, the next steps are typically an SNRI (venlafaxine or duloxetine), augmentation with mirtazapine or buspirone, or intensification of psychotherapy. Sustained benzodiazepine monotherapy is rarely the right answer even at that point.